The estimated Net Worth of H. Ralph Snodgrass is at least $780 Thousand dollars as of 17 August 2021. H Snodgrass owns over 3,750 units of Vistagen Therapeutics stock worth over $109,119 and over the last 8 years he sold VTGN stock worth over $0. In addition, he makes $671,255 as President, Founder, Chief Scientific Officer, and Director at Vistagen Therapeutics.
H has made over 3 trades of the Vistagen Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 3,750 units of VTGN stock worth $10,238 on 17 August 2021.
The largest trade he's ever made was buying 15,000 units of Vistagen Therapeutics stock on 20 November 2019 worth over $5,100. On average, H trades about 1,181 units every 49 days since 2016. As of 17 August 2021 he still owns at least 34,641 units of Vistagen Therapeutics stock.
You can see the complete history of H Snodgrass stock trades at the bottom of the page.
Dr. H. Ralph Snodgrass Ph.D. serves as President, Founder, Chief Scientific Officer, Director of the Company. He co-founded VistaGen California with Dr. Gordon Keller in 1998 and served as the Chief Executive Officer of VistaGen California until August 2009. Dr. Snodgrass has served as the President and Chief Scientific Officer of VistaGen California from inception to the present, and in the same positions with the Company following the completion of the Merger. He served as a member of the Board of Directors of VistaGen California from 1998 to 2011, and was appointed to serve on our Board after the completion of the Merger. Prior to founding VistaGen California, Dr. Snodgrass served as a key member of the executive management team that led Progenitor, Inc., a biotechnology company focused on developmental biology, through its initial public offering, and was its Chief Scientific Officer from June 1994 to May 1998, and its Executive Director from July 1993 to May 1994. He received his Ph.D. in immunology from the University of Pennsylvania, and has 28 years of experience in senior biotechnology management and over 10 year’s research experience as an assistant professor at the Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill School of Medicine, and as a member of the Institute for Immunology, Basel, Switzerland. Dr. Snodgrass is a past Board Member of the Emerging Company Section of the Biotechnology Industry Organization (BIO), and past member of the International Society of Stem Cell Research (ISSCR) Industry Committee. Dr. Snodgrass has published more than 95 scientific papers, is the inventor on more than 21 patents and a number of patent applications, has been the Principal Investigator on U.S. federal and private foundation sponsored research grants with budgets totaling more than $14.5 million and is recognized as an expert in stem cell biology with more than 32 years’ experience in the uses of stem cells as biological tools for research, drug discovery and development.
As the President, Founder, Chief Scientific Officer, and Director of Vistagen Therapeutics, the total compensation of H Snodgrass at Vistagen Therapeutics is $671,255. There are 2 executives at Vistagen Therapeutics getting paid more, with Shawn Singh having the highest compensation of $933,667.
H Snodgrass is 70, he's been the President, Founder, Chief Scientific Officer, and Director of Vistagen Therapeutics since 2011. There are 4 older and 11 younger executives at Vistagen Therapeutics. The oldest executive at Vistagen Therapeutics Inc. is Jon Saxe, 84, who is the Independent Chairman of the Board.
H's mailing address filed with the SEC is C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 8 years, insiders at Vistagen Therapeutics have traded over $147,300 worth of Vistagen Therapeutics stock and bought 1,944,506 units worth $18,208,989 . The most active insiders traders include Healthcare Capital Partners..., Capital Lp Commodore, and Jon S Saxe. On average, Vistagen Therapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $378,372. The most recent stock trade was executed by Capital Lp Commodore on 7 August 2023, trading 775,756 units of VTGN stock currently worth $17,958,751.
we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
Vistagen Therapeutics executives and other stock owners filed with the SEC include: